SAB BIOTHERAPEUTICS, INC. Comprehensive Income
SAB BIOTHERAPEUTICS, INC. (SABS) reported Comprehensive Income of -$23.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$23.20M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$19.28M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$16.75M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $45.53M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $13.60M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$34.27M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$42.17M.
- SAB BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$18.74M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$23.20M 10-Q · filed 2026-08-06 | -$42.48M 10-Q · filed 2026-08-06 | -$59.22M derived: sum of 3 quarters · filed 2026-08-06 | -$13.69M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$19.28M 10-Q · filed 2026-05-12 | -$36.02M derived: sum of 2 quarters · filed 2026-05-12 | $9.51M derived: sum of 3 quarters · filed 2026-05-12 | -$510.12K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$16.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.79M derived: sum of 2 quarters · filed 2026-03-09 | $18.77M derived: sum of 3 quarters · filed 2026-08-06 | $13.60M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $45.53M 10-Q · filed 2025-11-14 | $35.51M derived: sum of 2 quarters · filed 2026-08-06 | $30.34M 10-Q · filed 2025-11-14 | $18.76M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$10.02M 10-Q · filed 2026-08-06 | -$10.02M 10-Q · filed 2025-08-07 | -$15.19M 10-Q · filed 2026-08-06 | -$15.19M 10-Q · filed 2025-08-07 | -$26.77M derived: sum of 3 quarters · filed 2026-08-06 | -$37.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.17M 10-Q · filed 2026-05-12 | -$16.76M derived: sum of 2 quarters · filed 2026-05-12 | -$27.02M derived: sum of 3 quarters · filed 2026-05-12 | -$34.32M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$11.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$21.85M derived: sum of 2 quarters · filed 2026-03-09 | -$29.15M derived: sum of 3 quarters · filed 2026-03-09 | -$34.27M 10-K · filed 2026-03-09 | ||
| 2024-09-30 | -$10.27M 10-Q · filed 2025-11-14 | -$17.57M derived: sum of 2 quarters · filed 2025-11-14 | -$22.68M 10-Q · filed 2025-11-14 | -$45.52M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$7.30M 10-Q · filed 2025-08-07 | -$12.42M 10-Q · filed 2025-08-07 | -$35.25M derived: sum of 3 quarters · filed 2025-08-07 | -$40.35M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$5.12M 10-Q · filed 2025-05-09 | -$27.95M derived: sum of 2 quarters · filed 2025-05-09 | -$33.05M derived: sum of 3 quarters · filed 2025-05-09 | -$39.93M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$22.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$27.93M derived: sum of 2 quarters · filed 2025-03-31 | -$34.81M derived: sum of 3 quarters · filed 2025-03-31 | -$42.17M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$5.10M 10-Q · filed 2024-11-06 | -$11.98M derived: sum of 2 quarters · filed 2024-11-06 | -$19.34M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$6.88M 10-Q · filed 2024-08-08 | -$14.23M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | -$7.35M 10-Q · filed 2024-05-20 | |||||
| 2022-12-31 | -$18.74M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |